BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic...

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• ERK signaling is crucial for cell growth and is regulated by RAS-RAF interactions.
• Feedback inhibition normally limits RAS-RAF pathway activation.
• BRAF mutations can lead to constitutive pathway activation, driving cancer.

Purpose of the Study:

• To investigate the mechanisms by which activated BRAF mutants evade feedback inhibition.
• To understand the differential efficacy of RAF inhibitors against distinct BRAF mutant forms.
• To identify therapeutic strategies for overcoming resistance to RAF inhibitors.

Main Methods:

• Analysis of BRAF V600 mutants as monomers versus other BRAF mutants as dimers.
• Assessment of RAF inhibitor binding and efficacy against monomeric and dimeric BRAF.
• Evaluation of a novel compound targeting both sites of RAF dimers in preclinical models.

Main Results:

• BRAF V600 mutants function as monomers, while other activating BRAF mutants form dimers.
• RAF inhibitors are effective against monomers but poorly inhibit dimers due to reduced binding affinity.
• Tumors with dimeric BRAF mutants or acquired resistance via BRAF V600E dimerization are insensitive to current RAF inhibitors.
• A novel compound targeting both dimer binding sites demonstrated broad efficacy against both BRAF mutant classes and resistant tumors.

Conclusions:

• BRAF mutations activate the ERK pathway through distinct monomeric or dimeric mechanisms.
• RAF inhibitor efficacy is dependent on the specific BRAF mutation and its oligomeric state.
• Dual-acting RAF dimer inhibitors represent a promising therapeutic approach for a wider range of BRAF-driven cancers.